Traws Pharma Inc. (TRAW)
TRAW trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1130598/000110465926043832/0001104659-26-043832-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TRAW on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2013 |
| SEC CIK | 0001130598 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.8M |
| Net income | $9.2M |
| Operating income | -$17.9M |
| Net margin | 328.7% |
| Operating margin | -640.7% |
| Revenue growth | +1134.5% |
| Cash | $3.8M |
| Total assets | $10.6M |
| P/E (computed) | 0.4× |
| P/S (computed) | 1.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result of these conditions, substantial doubt exists about the Company's ability to continue as a going concern." | 10-Q 2026-08-14 |
| Cash and burn | $5.0M cash; operating cash flow -$4.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 15,368,277 (2026-08-12); 7,063,829 a year earlier; 20,977,625 three years earlier. 3y figure adjusted for splits (1-for-25 overall). | Cover page 2026-08-12 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2024-09-23 | Source 2024-09-23 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-07-10 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-07-31 |
| Auditor | KPMG LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-05-14 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-03-31 |
| Insider trades, 12 months | Bought $998K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$3.1M | -$7.5M | $5.0M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$7.1M | -$2.6M | $3.1M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $0 | -$7.4M | -$2.8M | $3.8M | No debt tags | $2.8M | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | $0 | -$4.0M | -$4.0M | $6.4M | No debt tags | $2.8M | 10-Q 2025-11-13 |
| Q2 2025 2025-06-30 | $2.7M | -$915K | -$6.0M | $13.1M | No debt tags | $2.9M | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | $57K | $21.5M | -$5.4M | $15.9M | No debt tags | $227K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $56K | -$29.9M | -$4.0M | $21.3M | No debt tags | $226K | 10-K 2026-04-15 |
| Q3 2024 2024-09-30 | $57K | -$8.5M | -$11.5M | $5.4M | No debt tags | $226K | 10-Q 2025-11-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-16 |
| Latest annual report | 10-K/A | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-10-20 |
Source: SEC EDGAR submissions feed, 994 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +13.6% |
| 1 month | -39.0% |
| 3 months | -58.3% |
| Year to date | -77.9% |
| 1 year | -85.9% |
| From 52-week high | -91.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IMNN | Imunon Inc. | $0.5940 | -5.56% | $3.9M |
| GELS | Gelteq Limited | $0.3589 | -5.63% | $3.8M |
| AZTR | Azitra Inc | $0.6270 | +3.06% | $3.8M |
| XTLB | XTL Biopharmaceuticals Ltd. | $1.54 | -3.75% | $3.8M |
| BGMS | Bio Green Med Solution Inc. | $0.6502 | +1.55% | $4.3M |
| KPRX | Kiora Pharmaceuticals Inc. | $0.9820 | -20.16% | $4.3M |
| NCNA | NuCana plc American Depositary Share | $0.8631 | -7.46% | $4.4M |
| XBIO | Xenetic Biosciences Inc. | $1.49 | -10.24% | $3.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier